Gregory C. Davis, Ph.D.
Greg Davis began his professional career in 1980 with Monsanto Agricultural Products Company studying the effects of endogenous plant growth hormones on reproductive processes and yield. In 1985, Greg joined the Biotechnology Product Development Group in the Control Division of the Upjohn Company. In 1987, Greg was named Director of that group at Upjohn.
In 1992, he joined Eli Lilly, where he held various leadership positions in Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. At the time of his retirement from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs. Greg has been active throughout his career in influencing the external environment on behalf of the pharmaceutical industry. He has held various leadership positions on PhRMA committees, USP, BIO, and was the PhRMA liaison to the International Conference on Harmonization for Q5 (Biotechnology) topics for five years.
Greg has expertise in both the scientific and regulatory aspects of monoclonal antibody and biosimilars development. He currently consults with biopharmaceutical companies on CMC development issues and regulatory affairs.
In 1992, he joined Eli Lilly, where he held various leadership positions in Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. At the time of his retirement from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs. Greg has been active throughout his career in influencing the external environment on behalf of the pharmaceutical industry. He has held various leadership positions on PhRMA committees, USP, BIO, and was the PhRMA liaison to the International Conference on Harmonization for Q5 (Biotechnology) topics for five years.
Greg has expertise in both the scientific and regulatory aspects of monoclonal antibody and biosimilars development. He currently consults with biopharmaceutical companies on CMC development issues and regulatory affairs.